Question 1 · Medium
Which pharmacogenetic variant reduces the antiplatelet effect of clopidogrel?
- ASLCO1B1 521T>C variant
- BCYP2D6 ultrarapid metaboliser status
- CCYP2C19 loss-of-function alleles
- DVKORC1 -1639 G>A variant
Show answerHide answer
Answer: C · CYP2C19 loss-of-function alleles
Clopidogrel is a prodrug activated mainly by CYP2C19. Carriers of loss-of-function alleles form less active metabolite and have a higher risk of stent thrombosis and recurrent events, so ticagrelor or prasugrel may be chosen.
- A: SLCO1B1 variants increase simvastatin myopathy risk.
- B: CYP2D6 variation matters for codeine and tamoxifen.
- D: VKORC1 variants alter warfarin dose requirements.
Remember this
CYP2C19 loss-of-function alleles reduce clopidogrel activation.